Over the past decade, China's innovative drug industry has undergone a quiet but profound transformation. In the first half of 2026 alone, China's National Medical Products Administration (NMPA) approved 38 Class 1 innovative new drugs. Meanwhile, the total value of out-licensing deals for Chinese innovative drugs approached $110 billion – already reaching 80% of the full-year 2025 total.

Behind these numbers lies a fundamental shift: China's pharmaceutical innovation has moved beyond mere quantity growth to genuine quality breakthroughs. For international patients considering treatment in China, this means more treatment options – and better ones.

I. Record-Breaking Approvals

China's drug approval system is accelerating at an unprecedented pace.

Year Class 1 Innovative Drugs Approved Key Milestone
2023 40 Steady growth
2024 48 Continued expansion
2025 76 58.3% year-on-year increase – all-time high
H1 2026 38 (20 chemical, 17 biologics, 1 TCM) 11 were novel-target, first-in-class Chinese drugs

What's most noteworthy is the improvement in quality. In 2025, only 4 of the 76 approved drugs were novel-target, first-in-class Chinese originals. In H1 2026, 11 of the 38 approvals were novel-target drugs – all domestically developed – covering oncology, anti-infection, endocrinology, and more.

💡 What this means for international patients: More innovative drugs mean more treatment options. China is transforming from a "generic drug powerhouse" into a "drug innovation powerhouse." International patients can access globally cutting-edge therapies here.

II. First-in-Class Drugs Are Emerging at an Unprecedented Pace

On June 22, 2026, in a single day, China's NMPA approved four First-in-Class Chinese innovative drugs:

Drug Name Developer Type Global First-in-Class Significance
Lunkan Yilongtuo Monoclonal Antibody SystImmune Bispecific ADC World's first approved bispecific ADC – targets EGFR × HER3
Shurui Jiao'ao CAR-T CARsgen CAR-T World's first approved CAR-T for solid tumors
Silewei Miba Monoclonal Antibody Genrix Bispecific antibody World's first rabies passive immunotherapy bispecific antibody
Peilaijianan Spray Pulai Pharma Antimicrobial peptide China's first antimicrobial peptide Class 1 new drug

These four drugs span four frontier areas: bispecific ADCs, solid-tumor cell therapy, bispecific passive antibodies, and non-traditional antimicrobial mechanisms – all global firsts developed by Chinese companies.

Additionally, in H1 2026, China approved:

  • The world's first monoclonal antibody targeting both hepatitis B and hepatitis D
  • China's first domestically developed global-first radiopharmaceutical
💡 What this means for international patients: If you're seeking treatment for cancer, infectious disease, or other complex conditions, China is now a destination where you can access therapies that don't yet exist anywhere else in the world.

III. ADC: China Is Leading the Global Race

ADCs (Antibody-Drug Conjugates) – often called "biological missiles" that precisely kill cancer cells while sparing healthy tissue – are one of the hottest areas in global oncology R&D. China is now at the forefront of this field.

In 2026 alone, ADC out-licensing deals from China have been breaking records almost weekly. Key examples:

  • SystImmune: In 2023, licensed the global rights for its bispecific ADC BL-B01D1 to BMS for $800 million upfront, with a total deal value of $8.4 billion – China's largest single out-licensing record. In June 2026, the drug received NMPA approval for nasopharyngeal carcinoma, becoming the world's first approved bispecific ADC.
  • Kelun-Biotech: Signed a cumulative deal with Merck (MSD) worth over $11.8 billion, covering 7 ADC assets.
  • CTTQ: Its GPC3-targeting ADC (TQB6426) received U.S. FDA IND clearance in September 2026, targeting hepatocellular carcinoma – a cancer type particularly prevalent in Asia.
💡 What this means for international patients: China offers access to the world's most advanced ADC technologies – and at a fraction of the cost you'd pay elsewhere.

IV. Cell & Gene Therapy: Opening New Frontiers

In 2025, China registered 2,997 new clinical trials for drugs. Among them, cell and gene therapy trials showed significant growth, with oncology remaining the primary indication.

By the end of 2025:

  • 827 Chinese-origin innovative drugs entered clinical trials for the first time – ranked #1 globally, accounting for 47.4% of the world total.
  • Of the 14,088 innovative drugs in global R&D pipelines, Chinese-origin drugs accounted for 4,751 (33.7%) – surpassing the U.S. (4,019, 28.5%) to claim the global #1 position.

In CAR-T cell therapy, CARsgen's Shurui Jiao'ao received approval for solid tumors – breaking the long-held belief that CAR-T only works in hematological malignancies. This breakthrough has brought new hope to countless solid-tumor patients worldwide.

💡 What this means for international patients: China is now the world's largest source of innovative drug candidates. For patients with difficult-to-treat cancers, China offers early access to next-generation therapies that may not yet be available in your home country.

V. Going Global: From "Selling the Pipeline" to Global Commercialization

Chinese innovative drugs are gaining international recognition at an accelerating pace.

By the numbers:

Year Out-Licensing Deals Total Deal Value
2024 94 deals $51.9 billion
2025 157 deals $135.66 billion
H1 2026 – ~$110 billion (already 80% of 2025's full-year total)

Landmark events:

  • July 2025: Dizal Pharma's Sunvozertinib received U.S. FDA accelerated approval – becoming the world's first EGFR exon20ins-targeting lung cancer drug approved in the U.S.
  • April 2025: Akeso's Penpulimab received U.S. FDA approval for nasopharyngeal carcinoma.
  • BeiGene's Zanubrutinib – a BTK inhibitor – is now approved in over 75 markets globally, with 2025 global sales growing nearly 50% year-on-year.
💡 What this means for international patients: Chinese drugs are now being approved by the U.S. FDA and other major regulatory bodies. This means the therapies you receive in China meet international standards – and are increasingly available worldwide.

VI. Regulatory Reform: The "Accelerator" Behind Innovation

The rapid development of China's innovative drugs would not have been possible without sweeping regulatory reforms.

Approval timelines have compressed dramatically:

Period Average NDA Review Time
Pre-2015 26 – 30 months
Current (standard) 12 – 16 months
Priority review 10 – 12 months
Conditional approval ~8 months (fastest)

Key reforms:

  • Conditional Approval: Allows drugs to be approved based on Phase II clinical data, with post-approval confirmatory studies required.
  • IND 60-Day Silent Approval: Clinical trial applications automatically proceed if no objection is received within 60 days.
  • Priority Review & Approval: Expedited pathway for innovative drugs.

This regulatory framework has made China one of the fastest markets in the world for innovative drug approvals.

Conclusion

From follower to competitor, and now to leader in ADCs, CAR-T, bispecific antibodies, and beyond – China's innovative drug industry is undergoing a profound transformation.

In 2025, China approved 76 innovative new drugs. In the first half of 2026, 11 novel-target Chinese-origin drugs were approved – drugs that didn't exist before, developed by Chinese scientists, for patients worldwide.

For international patients considering treatment in China, this means:

  • ✅ More choices – a wider range of therapies
  • ✅ Faster access – drugs reach patients sooner
  • ✅ Better value – world-class innovation at competitive prices

World-class innovative drugs are now being born in China.

📌 Data sources: National Medical Products Administration (NMPA), Xinhua News, Economic Reference News, China Food and Drug Administration Magazine, publicly available reports (2025–2026).